Keywords
General report ×
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

- 9/20/21 - 2 forms, 9 itemgroups, 52 items, 2 languages
Itemgroups: Care problem, Score, Care goal, Nursing procedure, Activities of daily living, Homecare Status, Social Environment, Legal Aspects, Medical information

Header

3 itemgroups, 18 items
- 9/20/21 - 1 form, 21 itemgroups, 284 items, 1 language
Itemgroups: GENERAL INFORMATION TEAM, GENERAL INFORMATION PATIENT, DISEASE, AL AMYLOIDOSIS INITIAL DIAGNOSIS, ORGAN INVOLVEMENT AT DIAGNOSIS, PRE-HSCT TREATMENT, HSCT, STATUS OF DISEASE AT COLLECTION (AUTOGRAFTS ONLY), STATUS OF DISEASE AT START OF CONDITIONING FOR BMT, STATUS OF DISEASE AT 100 DAYS AFTER HSCT, ORGAN-SPECIFIC RESPONSES AT 100 DAYS AFTER HSCT, FORMS TO BE FILLED IN, FOLLOW UP AL AMYLOIDOSIS, PATIENT LAST SEEN, GRAFT VERSUS HOST DISEASE (GvHD) SINCE LAST REPORT, OTHER COMPLICATIONS SINCE LAST REPORT, GRAFT ASSESSMENT AND HAEMOPOIETIC CHIMAERISM, ADDITIONAL THERAPIES SINCE LAST FOLLOW UP, FIRST EVIDENCE OF DISEASE WORSENING SINCE LAST HSCT, LAST DISEASE AND PATIENT STATUS, ADDITIONAL NOTES IF APPLICABLE
- 9/20/21 - 1 form, 1 itemgroup, 95 items, 2 languages
Itemgroup: General report
- 9/17/21 - 1 form, 16 itemgroups, 118 items, 1 language
Itemgroups: GENERAL INFORMATION, Patient, Disease, SYSTEMIC LUPUS ERITHEMATOSUS (SLE), INITIAL DIAGNOSIS, DIAGNOSTIC CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS, FIRST LINE THERAPIES, DATE OF HSCT, STATUS OF DISEASE AT MOBILISATION, SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) score, LABORATORY VALUES, PATIENT’S SELF ASSESSMENT PRIOR TO MOBILISATION, HEALTH ASSESSMENT QUESTIONNAIRE (HAQ), STATUS OF DISEASE AT HSCT, ADDITIONAL TREATMENT POST-HSCT, FORMS TO BE FILLED IN
- 3/25/20 - 1 form, 7 itemgroups, 40 items, 2 languages
Itemgroups: Administrative Data, Life situation, Education and employment, Occupational status, Nicotine consumption, Alcohol consumption, Vital signs
DELCODE is conducted by DZNE, the German Center for Neurodegenerative Diseases within the Helmholtz Association. The following information was taken from https://www.dzne.de/en/research/studies/clinical-studies/delcode/. Background and aims: One of the important aims of research into Alzheimer's is to find ways of detecting the disease early – if at all possible, as soon as the first minor symptoms appear, or even before any symptoms at all have appeared. Such detection capabilities are the necessary basis for development of therapies that can be applied at such early stages in the disease. Recent research indicates that such therapies could be more effective than therapies initiated during the disease's later stages. Over a period of several years, the DELCODE study is studying persons in early stages of the disease, along with various risk groups. The research is aimed at the development of procedures for characterizing early stages of the disease, at improving prediction of the course of the disease and at identifying new markers for early diagnosis of Alzheimer's-related dementia. Overview: DELCODE is set up to run for an initial period of three years, and to include a total of 1,000 study participants, who will be examined on a yearly basis. The group of participants will include persons with no complaints (healthy control subjects), patients with slight memory impairment or mild dementia and first-degree relatives of patients with diagnosed Alzheimer's disease. The minimum age for participants is 60. Course of the study: The examinations in the framework of the study will include a comprehensive interview carried out by a study investigator, a detailed neuropsychological examination (testing of memory functions and other areas of cognitive performance), a blood test and a cranial MRI scan. Optionally, subject to the study participant's consent in each case, a lumbar puncture (collection of cerebrospinal fluid) will be carried out." For more information (e.g. principle investigator and study coordination), please visit the above link or https://www.dzne.de. This document contains the General aspects Baseline form. It has to be filled in at the baseline of the study.
- 3/23/20 - 1 form, 8 itemgroups, 29 items, 1 language
Itemgroups: Administrative Data, Cumulative documentation, Informed consent, Life situation, Occupational status, Nicotine consumption, Alcohol consumption, Vital signs
DELCODE is conducted by DZNE, the German Center for Neurodegenerative Diseases within the Helmholtz Association. The following information was taken from https://www.dzne.de/en/research/studies/clinical-studies/delcode/. Background and aims: One of the important aims of research into Alzheimer's is to find ways of detecting the disease early – if at all possible, as soon as the first minor symptoms appear, or even before any symptoms at all have appeared. Such detection capabilities are the necessary basis for development of therapies that can be applied at such early stages in the disease. Recent research indicates that such therapies could be more effective than therapies initiated during the disease's later stages. Over a period of several years, the DELCODE study is studying persons in early stages of the disease, along with various risk groups. The research is aimed at the development of procedures for characterizing early stages of the disease, at improving prediction of the course of the disease and at identifying new markers for early diagnosis of Alzheimer's-related dementia. Overview: DELCODE is set up to run for an initial period of three years, and to include a total of 1,000 study participants, who will be examined on a yearly basis. The group of participants will include persons with no complaints (healthy control subjects), patients with slight memory impairment or mild dementia and first-degree relatives of patients with diagnosed Alzheimer's disease. The minimum age for participants is 60. Course of the study: The examinations in the framework of the study will include a comprehensive interview carried out by a study investigator, a detailed neuropsychological examination (testing of memory functions and other areas of cognitive performance), a blood test and a cranial MRI scan. Optionally, subject to the study participant's consent in each case, a lumbar puncture (collection of cerebrospinal fluid) will be carried out." For more information (e.g. principle investigator and study coordination), please visit the above link or https://www.dzne.de. This document contains the General aspects form. It has to be filled in at follow-up visits of the study.
- 12/7/18 - 1 form, 7 itemgroups, 42 items, 1 language
Itemgroups: Administrative data, Mothers relevant medical/family history, Number of previous pregnancies, Fathers relevant medical/family history, DRUG EXPOSURES, Withdraw from study, REPORTING INVESTIGATOR INFORMATION